Ochre Bio is a biotechnology company developing RNA medicines for chronic liver disease by using advances in ‘deep phenotyping’ and testing our therapeutics directly in human livers kept alive on machines. Situated within the heart of Oxford’s biotech innovation hub, with further labs in Taipei and New York, Ochre is built on over 15 years’ experience in liver genomics and bringing advanced therapies to market.